CVS Health (CVS) Projected to Post Quarterly Earnings on Wednesday

CVS Health (NYSE:CVS) is expected to be announcing its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect the company to announce earnings of $2.21 per share and revenue of $94.9685 billion for the quarter. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 8:00 AM ET.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, topping the consensus estimate of $1.00 by $0.09. The business had revenue of $105.69 billion for the quarter, compared to analysts’ expectations of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The company’s quarterly revenue was up 8.2% compared to the same quarter last year. During the same quarter last year, the company posted $1.19 earnings per share. On average, analysts expect CVS Health to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

CVS Health Stock Up 0.0%

Shares of CVS Health stock opened at $82.12 on Monday. The business has a 50-day moving average price of $76.32 and a 200 day moving average price of $77.96. CVS Health has a fifty-two week low of $58.35 and a fifty-two week high of $85.15. The firm has a market cap of $105.24 billion, a P/E ratio of 59.51, a P/E/G ratio of 0.86 and a beta of 0.60. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd will be given a $0.665 dividend. The ex-dividend date is Thursday, April 23rd. This represents a $2.66 annualized dividend and a dividend yield of 3.2%. CVS Health’s dividend payout ratio (DPR) is presently 192.75%.

Wall Street Analysts Forecast Growth

CVS has been the topic of several research reports. Sanford C. Bernstein raised CVS Health from a “market perform” rating to an “outperform” rating and upped their price target for the company from $91.00 to $94.00 in a research report on Thursday, March 12th. Wolfe Research lowered their target price on shares of CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a research note on Monday, March 2nd. The Goldman Sachs Group increased their target price on shares of CVS Health from $95.00 to $97.00 and gave the stock a “buy” rating in a report on Thursday, February 12th. Argus reduced their price target on shares of CVS Health from $91.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, January 28th. Finally, Bank of America lowered their price objective on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a research report on Tuesday, January 27th. Twenty equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $95.05.

Institutional Investors Weigh In On CVS Health

A number of hedge funds have recently added to or reduced their stakes in the stock. Wellington Management Group LLP grew its position in shares of CVS Health by 193.2% during the fourth quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator’s stock worth $1,473,270,000 after acquiring an additional 12,233,675 shares during the last quarter. Amundi lifted its position in CVS Health by 95.3% in the 3rd quarter. Amundi now owns 7,453,980 shares of the pharmacy operator’s stock valued at $572,665,000 after purchasing an additional 3,637,943 shares during the last quarter. Morgan Stanley boosted its stake in CVS Health by 6.3% during the 4th quarter. Morgan Stanley now owns 20,373,774 shares of the pharmacy operator’s stock valued at $1,616,863,000 after purchasing an additional 1,211,631 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in CVS Health by 148.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,467,170 shares of the pharmacy operator’s stock worth $110,610,000 after purchasing an additional 876,443 shares during the last quarter. Finally, Maple Rock Capital Partners Inc. acquired a new stake in shares of CVS Health in the fourth quarter valued at approximately $64,790,000. 80.66% of the stock is currently owned by institutional investors.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.